<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31787970</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment.</ArticleTitle><Pagination><StartPage>2564</StartPage><MedlinePgn>2564</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2564</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2019.02564</ELocationID><Abstract><AbstractText>Enterovirus and Coxsackievirus are the major viruses that cause hand, foot, and mouth disease (HFMD) outbreaks worldwide. Several studies have shown the potential of viral envelope protein 1 (VP1) on providing protective effects from viral strains of different genotypes. However, whether VP1 has the cross-protection in Enteroviruses or Coxsackievirus has not been studied in-depth. In this study, the <i>vp1</i> gene of Enterovirus 71 (EV71) and Coxsackievirus B3 (CB3) was inserted into the vector pET22b (+) to form the respective expression plasmids pEVP1 or pCVP1, and then transformed into <i>Escherichia coli</i> strain BL21 (DE3). The recombinant EVP1 or CVP1 protein was overexpressed successfully and effectively purified to homogeneity. Then, we identified that EVP1 and CVP1 protein could generate effectively specific humoral immunity and cellular immunity in mice, what's more, we determined the cross-protection of VP1 between EV71 and CB3 in a murine model. The results showed that immunization with EVP1 could effectively induce specific IgG and secretory IgA against CVP1 and the sera from EVP1-immunized mice could neutralize CB3 with mean titers 1:440. In contrast, no measurable neutralizing antibodies to EV71 were detected in CVP1-immunized mice. Then, newborn BALB/C mice, whose mother was immunized with EVP1 or CVP1, were administered with different lethal doses of EV71 or CB3. The EVP1 immunized group showed a 90% protective efficacy for a CB3 dosage of 120 LD<sub>50</sub>, but the CVP1 immunized group showed no significantly different protective efficacy against 15 LD<sub>50</sub> of EV71 compared with the BSA immunized group. Hence, EVP1 is a promising subunit vaccine candidate against Enterovirus 71 and Coxsackievirus B3 caused HFMD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Chen, Liu, Fang, Nan, Li, Ning, Luo, Li and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fang-Hong</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Anhui Medical University, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PLA Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Hua-Li</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Anhui Medical University, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nan</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Nian-Zhi</ForeName><Initials>NZ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>De-Yan</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Anhui Medical University, Anhui, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064789" MajorTopicYN="N">Immunity, Heterologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015678" MajorTopicYN="N">Viral Structural Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">VP1 protein</Keyword><Keyword MajorTopicYN="N">cross-protection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31787970</ArticleId><ArticleId IdType="pmc">PMC6856078</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.02564</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andr&#xe9;s C, Guasch E, Pi&#xf1;ana M, Fernandes P, Gimferrer L, Esso D, et al. . Recombinant CV-A6 strains related to hand-foot-mouth disease and herpangina at primary care centers (Barcelona, Spain). Fut Microbiol. (2019) 14:499&#x2013;507. 10.2217/fmb-2018-0336</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2018-0336</ArticleId><ArticleId IdType="pubmed">31033351</ArticleId></ArticleIdList></Reference><Reference><Citation>Borkakoty B, Das M, Jakharia A, Bhattacharya C, Bora C, Baruah P, et al. . Hand, foot and mouth disease caused by Coxsackie viruses A6 and A16 in Assam, Northeast India: a need for surveillance. Indian J Dermatol Venereol Leprol. (2019). 10.4103/ijdvl.IJDVL_576_17. [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijdvl.IJDVL_576_17</ArticleId><ArticleId IdType="pubmed">30860171</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrerizo M, D&#xed;az-Cerio M, Mu&#xf1;oz-Almagro C, Rabella N, Tarrag&#xf3; D, Romero MP, et al. . Molecular epidemiology of enterovirus and parechovirus infections according to patient age over a 4-year period in Spain. J Med Virol. (2017) 89:435&#x2013;42. 10.1002/jmv.24658</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24658</ArticleId><ArticleId IdType="pubmed">27505281</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisterna DM, Lema CL, Martinez LM, Ver&#xf3;n E, Contarino LP, Acosta D, et al. . Atypical hand, foot, and mouth disease caused by Coxsackievirus A6 in Argentina in 2015. Rev Argent Microbiol. (2019) 51:140&#x2013;3. 10.1016/j.ram.2018.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ram.2018.05.003</ArticleId><ArticleId IdType="pubmed">30269935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang MTV, Nguyen TA, Tran TT, Vu TTH, Le NTN, Nguyen THN, et al. . Clinical and aetiological study of hand, foot and mouth disease in southern Vietnam, 2013&#x2013;2015: inpatients and outpatients. Int J Infect Dis. (2019) 80:1&#x2013;9. 10.1016/j.ijid.2018.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2018.12.004</ArticleId><ArticleId IdType="pmc">PMC6403263</ArticleId><ArticleId IdType="pubmed">30550944</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieczorek M, Cia&#x327;&#x107;ka A, Krzysztoszek A, Figas A, Szenborn L. Genetic Characterization of human enteroviruses associated with hand, foot and mouth diseases in Poland, 2013&#x2013;2016. Polish J Microbiol. (2017) 66:405&#x2013;9. 10.5604/01.3001.0010.4889</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/01.3001.0010.4889</ArticleId><ArticleId IdType="pubmed">29319516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitomi H, Ashizuka Y, Ichihara S, Nakamura T, Nakamura A, Kobayashi T, et al. . Molecular epidemiology of coxsackievirus A6 derived from hand, foot, and mouth disease in Fukuoka between 2013 and 2017. J Med Virol. (2018) 90:1712&#x2013;9. 10.1002/jmv.25250</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25250</ArticleId><ArticleId IdType="pubmed">29981169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai K, Wang Y, Guo Z, Yu H, Li H, Zhang L, et al. . Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China. BMC Infect Dis. (2019) 19:285. 10.1186/s12879-019-3878-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-3878-6</ArticleId><ArticleId IdType="pmc">PMC6438032</ArticleId><ArticleId IdType="pubmed">30917800</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GP, Wu JB, Wang JJ, Pan HF, Zhang J, Shi YL, et al. . Epidemiological characteristics and influential factors of hand, foot and mouth disease (HFMD) reinfection in children in Anhui province. Epidemiol Infect. (2016) 144:153&#x2013;60. 10.1017/S0950268815001107</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268815001107</ArticleId><ArticleId IdType="pmc">PMC9507301</ArticleId><ArticleId IdType="pubmed">26027435</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Wei H, Wu S, Du Y, Liu L, Su J, et al. . Epidemiological and etiological characteristics of hand, foot, and mouth disease in Henan, China, 2008-2013. Sci Rep. (2015) 5:8904. 10.1038/srep08904</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep08904</ArticleId><ArticleId IdType="pmc">PMC4354091</ArticleId><ArticleId IdType="pubmed">25754970</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SL, Pan H, Liu P, Amer S, Chan TC, Zhan J, et al. . Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol. (2015) 25:115&#x2013;28. 10.1002/rmv.1827</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Teng Z, Cui X, Li C, Pan H, Zheng Y, et al. Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012-2016 article. Emerg Microbes Infect. (2018) 7:8 10.1038/s41426-017-0011-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-017-0011-z</ArticleId><ArticleId IdType="pmc">PMC5837173</ArticleId><ArticleId IdType="pubmed">29362406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Teng Z, Chu W, Fang F, Cui X, Guo X, et al. . The emergence and spread of one Coxsackievirus A16 Genogroup D novel recombinant strain that caused a clustering HFMD outbreak in Shanghai, China, 2016. Emerg Microbes Infect. (2018) 7:131. 10.1038/s41426-018-0134-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0134-x</ArticleId><ArticleId IdType="pmc">PMC6052075</ArticleId><ArticleId IdType="pubmed">30022051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zhang H, Liu H, Zhang J, He L, Sun H, et al. . Molecular characteristics of hand, foot, and mouth disease for hospitalized pediatric patients in Yunnan, China. Medicine. (2018) 97:e11610. 10.1097/MD.0000000000011610</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011610</ArticleId><ArticleId IdType="pmc">PMC6081097</ArticleId><ArticleId IdType="pubmed">30075535</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li C, He D, Cheng T, Ge S, Shih JWK, et al. Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine. (2013) 31:425&#x2013;30. 10.1016/j.vaccine.2012.10.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.032</ArticleId><ArticleId IdType="pubmed">23088887</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. (2018) 37:391&#x2013;8. 10.1007/s10096-018-3206-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Modlin JF, Rotbart HA. Group B Coxsackie disease in children. In Tracy S, Chapman NM, Mahy BWJ. editors. The Coxsackie B Viruses. Current Topics in Microbiology and Immunology. Vol. 223 Berlin; Heidelberg: Springer; (2011). p. 53&#x2013;80. 10.1007/978-3-642-60687-8_4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-60687-8_4</ArticleId><ArticleId IdType="pubmed">9294925</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo C, Wigdorovitz A, Oliveros JC, Zamorano PI, Sadir AM, G&#xf3;mez N, et al. . Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J Virol. (1998) 72:1688&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124657</ArticleId><ArticleId IdType="pubmed">9445079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H-F, Chang M-H, Chiang B-L, Jeng S-T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. (2006) 24:2944&#x2013;51. 10.1016/j.vaccine.2005.12.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, et al. . Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. (1979) 60:329&#x2013;40. 10.1007/BF01317504</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317504</ArticleId><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke A, Zell R, Stelzner A. DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice. Antiviral Res. (2001) 49:49&#x2013;54. 10.1016/S0166-3542(00)00132-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-3542(00)00132-7</ArticleId><ArticleId IdType="pubmed">11166860</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Li YS, Chiou CC, Suen PC, Lin TY, Chang LY, et al. . Expression of caspid protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection. J Med Virol. (2000) 61:228&#x2013;34. 10.1002/(SICI)1096-9071(200006)61:2&lt;228::AID-JMV9&gt;3.0.CO;2-R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(200006)61:2&lt;228::AID-JMV9&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">10797379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-N, Lin Y-C, Fann C, Liao N-S, Shih S-R, Ho M-S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. (2001) 20:895&#x2013;904. 10.1016/S0264-410X(01)00385-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukashev AN, Lashkevich VA, Ivanova OE, Koroleva GA, Hinkkanen AE, Ilonen J. Recombination in circulating Human enterovirus B: independent evolution of structural and non-structural genome regions. J Gen Virol. (2005) 86:3281&#x2013;90. 10.1099/vir.0.81264-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81264-0</ArticleId><ArticleId IdType="pubmed">16298973</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS, Pe&#xf1;aranda S, Maher K, Pallansch MA. Complete genome sequences of all members of the species Human enterovirus A. J Gen Virol. (2004) 85:1597&#x2013;607. 10.1099/vir.0.79789-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79789-0</ArticleId><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T-C, Wang Y-F, Lee Y-P, Wang J-R, Liu C-C, Wang S-M, et al. . Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol. (2007) 81:10310&#x2013;5. 10.1128/JVI.00372-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00372-07</ArticleId><ArticleId IdType="pmc">PMC2045469</ArticleId><ArticleId IdType="pubmed">17626076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman AJ. Hsiung's diagnostic virology: As ilustrated by light and electron microscopy. West Haven: Yale University Press; (1994). 10.1016/0166-0934(94)90153-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-0934(94)90153-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. (2012) 8:e1002829. 10.1371/journal.pcbi.1002829</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002829</ArticleId><ArticleId IdType="pmc">PMC3531324</ArticleId><ArticleId IdType="pubmed">23300419</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang S, Zheng D, Standley DM, Yao B, Zacharias M, Zhang C. EPSVR and EPMeta: prediction of antigenic epitopes using support vector regression and multiple server results. BMC Bioinformatics. (2010) 11:381. 10.1186/1471-2105-11-381</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-11-381</ArticleId><ArticleId IdType="pmc">PMC2910724</ArticleId><ArticleId IdType="pubmed">20637083</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Alonso S, Phoon MC, Ramachandran NP, Chow VTK, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. (2007) 125:61&#x2013;8. 10.1016/j.virusres.2006.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DGW, Ang RX, Alonso S, Chow VTK, Quak SH, Poh CL. Identification of immunodominant VP1 linear epitope of enterovirus71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in western blots. Clin Microbiol Infect. (2008) 14:286&#x2013;8. 10.1111/j.1469-0691.2007.01904.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2007.01904.x</ArticleId><ArticleId IdType="pubmed">18076666</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhu R, Qian Y, Deng J, Sun Y, Liu L, et al. . Comparing enterovirus 71 with coxsackievirus A16 by analyzing nucleotide sequences and antigenicity of recombinant proteins of VP1s and VP4s. BMC Microbiol. (2011) 11:246. 10.1186/1471-2180-11-246</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-11-246</ArticleId><ArticleId IdType="pmc">PMC3217892</ArticleId><ArticleId IdType="pubmed">22050722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Wen K, Pan Y, Wang Y, Che X, Wang B. Cross-reactivity of anti-Ev71 IgM and neutralizing antibody in series sera of patients infected with enterovirus 71 and Coxsackievirus A 16. J Immunoass Immunochem. (2011) 32:233&#x2013;43. 10.1080/15321819.2011.559297</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15321819.2011.559297</ArticleId><ArticleId IdType="pubmed">21574094</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang WC, Huang LM, Kao CL, Lu CY, Shao PL, Cheng AL, et al. . Seroprevalence of enterovirus 71 and no evidence of crossprotection of enterovirus 71 antibody against the other enteroviruses in kindergarten children in Taipei city. J Microbiol Immunol Infect. (2012) 45:96&#x2013;101. 10.1016/j.jmii.2011.09.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2011.09.025</ArticleId><ArticleId IdType="pubmed">22154997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>